Erlotinib Completed Phase 1 Trials for Head and Neck Carcinoma Prevention

IndicationsStatusPurposePhase
CompletedPrevention1
clinicaltrials.gov IdentifierTitleDrugs
NCT00400374Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2